Histogen's FINAL Phase I/IIa Results (2013)
Collapse
X
-
The real question will be wether it'll be possible to continuously take shots to get some good results in combination with a good HT and other stuff.
But don't forget phase 2B will be about optimizing the product. Hopefully they can do better and we will have an upper limit for how much of the substance we can have us injected with.Comment
-
Chill out dude, don't take it personal. I'm just basing my comment on what I've read here on this forum, on how Histogen has supposedly communicated towards several people that they're currently looking for an investor. And with those really disappointing results that's going to be quite difficult in my opinion. No way I'd invest a dime into this company with those results.Comment
-
Hey guys,
Histogen has finally published the results of their 12 month Phase I/IIa results. Here's the link:
There's a lot of information which is provided and requires extensive discussion.
1) Duration of Efficacy: Although the patients remained above baseline at the 48 week follow-up, the effects started to wear off by that point: % Change from baseline: 19% (Week 12) compared to 12% (Week 36). This means that patients will need booster shots at least ONCE A YEAR.
Also, isn't it odd how they haven't provided data on % change from baseline for the 48th week even though they did measure it! (Food for thought)
2) Total Hair count in the Temporal Region (temples) increased only by 2.5% at the 48 week follow-up.
3) Therapeutic Window: They found a direct relationship between dose and possible toxicity (Haemoglobin count). Therefore, only so many mL of HSC can be injected at a given session. Otherwise, your Haemoglobin levels may drop and lead to anaemia and other related conditions. This is very important, as it means you cannot get Histogen injected all over your scalp in a single session... HSC will be simply used in your most problematic areas to give you that extra boost in hair density.
4) Safety: using only 8 shots of HSC lead to no abnormal parameters in trial subjects. Furthermore, all reported side effects were mild and transient, which is a big plus.
3 and 4) We don't know yet how often and how much can be injected. Assuming your deduction of an upper limit is correct, I wouldn't conclude the maximum level than can be injected is insufficient for significant growth and results. I think this is where phase 2B comes in, but we don't know that this is a major problem. They could figure out strategies to inject larger amounts in such ways not to increase significantly the risk of dangerous side effects.Comment
-
Well at least to me it's new that the effects start to wear of within 24 weeks already. Maybe even much sooner. And that HSC decreases hemoglobin production. And that it thus seems like you'll need at least 2 shots/year but that would risk hemoglobin levels (and even if it didn't, then it would still be a huge hassle to visit them twice a year for injections for only a marginal improvement).Comment
-
Chill out dude, don't take it personal. I'm just basing my comment on what I've read here on this forum, on how Histogen has supposedly communicated towards several people that they're currently looking for an investor. And with those really disappointing results that's going to be quite difficult in my opinion. No way I'd invest a dime into this company with those results.
Also, you are the perfect example of why need the forum to be reorganized in a way so that official information is stored and quickly accessible.
You deducted Histogen ran out of money. That is not true; Dr. Naughton released an interview with the MIT Enterprise Forum of San Diego back in Octoer/November stating they were looking for a partner with considerable financial and marketing weight to accompany them into their later stages of product development, and then eventually rely on their marketing power to launch the product the right way.
This is what Replicel is also doing, and what a lot of biotechs have been doing increasingly in recent years because of how tough it is to fund this type of research. As you may have noticed in fact, additional funding to Replicel will come only if they meet certain milestones...
Apparently some of us have received emails from someone at Histogen that any additional funds would be welcome. This is what you have read and this is not equivalent to saying they have no money.Comment
-
I'm very calm.
Also, you are the perfect example of why need the forum to be reorganized in a way so that official information is stored and quickly accessible.
You deducted Histogen ran out of money. That is not true; Dr. Naughton released an interview with the MIT Enterprise Forum of San Diego back in Octoer/November stating they were looking for a partner with considerable financial and marketing weight to accompany them into their later stages of product development, and then eventually rely on their marketing power to launch the product the right way.
This is what Replicel is also doing, and what a lot of biotechs have been doing increasingly in recent years because of how tough it is to fund this type of research. As you may have noticed in fact, additional funding to Replicel will come only if they meet certain milestones...
Apparently some of us have received emails from someone at Histogen that any additional funds would be welcome. This is what you have read and this is not equivalent to saying they have no money.Comment
-
Maybe even much sooner. And that HSC decreases hemoglobin production. And that it thus seems like you'll need at least 2 shots/year but that would risk hemoglobin levels (and even if it didn't, then it would still be a huge hassle to visit them twice a year for injections for only a marginal improvement).
What I'm telling you guys and Desmond is that they don't know that upper bound yet, and that's what they'll work on in phase 2B.Comment
-
Wrong again; not an investor, a partner that will be willing to give them money and infrastructure in exchange of royalties. It was meant to be that way all along and it is meant to be that way for most of these companies. It's called a business plan. They already had early stage investors.Comment
-
Regarding Temporal recession
Further, subjects receiving HSC in the temporal recession, which is known to be more difficult to treat than other areas of hair loss, saw marked improvement in terminal hair count, with a mean increase 25.2% at the 24 week time point.
25.2% increase is perfect..
It's the first PROVEN product to regrow hair on temples..Comment
-
Well no one ever promised your hair would be back to where it was on its own. I bet if you had read and informed yourself you would have noticed that the fact that benefits decay overtime. Let me tell you now: this is like botox in the sense that it's an injection of some stuff that makes you look better for some time because it adds longevity to your skin, but it doesn't "reprogram" the behavior of that skin telling it to go back to what it was before.Comment
-
Wrong again; not an investor, a partner that will be willing to give them money and infrastructure in exchange of royalties. It was meant to be that way all along and it is meant to be that way for most of these companies. It's called a business plan. They already had early stage investors.Comment
-
http://www.histogen.com/applications/hsc.htm
25.2% increase is perfect..
It's the first PROVEN product to regrow hair on temples..Comment
Comment